These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Millennium losing its independence. Cancer Discov; 2013 Jul; 3(7):OF4. PubMed ID: 23847379 [TBL] [Abstract][Full Text] [Related]
8. Obtaining financial support for patients receiving off-label drugs. Clancey JK; Card IC Oncol Nurs Forum; 2000 Jun; 27(5):769-70. PubMed ID: 10868389 [No Abstract] [Full Text] [Related]
9. Cost to the NHS of Roche oncology treatments. Sikora K J R Soc Med; 2007 Sep; 100(9):396-7. PubMed ID: 17766899 [No Abstract] [Full Text] [Related]
10. Cancer drug prices and the free-market forces. Kantarjian H; Zwelling L Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953 [No Abstract] [Full Text] [Related]
11. Role of financial relationships in economic analyses of targeted therapies in oncology remains unclear. Conter HJ J Clin Oncol; 2012 Nov; 30(31):3895; author reply 3895. PubMed ID: 23008317 [No Abstract] [Full Text] [Related]
12. Market spiral pricing of cancer drugs. Light DW; Kantarjian H Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792 [No Abstract] [Full Text] [Related]
13. 'Financial toxicity' looms as cancer combinations proliferate. Morrison C Nat Biotechnol; 2015 Aug; 33(8):783-4. PubMed ID: 26252117 [No Abstract] [Full Text] [Related]
14. Biomedicine. Pharma firms push for sharing of cancer trial data. Bhattacharjee Y Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862 [No Abstract] [Full Text] [Related]
16. Cost to the NHS of Roche oncology treatments. Atkins M J R Soc Med; 2007 Jul; 100(7):303. PubMed ID: 17606744 [No Abstract] [Full Text] [Related]
17. Sticker shock sharpens focus on biologics. McNeil C J Natl Cancer Inst; 2007 Jun; 99(12):910-2, 914. PubMed ID: 17565148 [No Abstract] [Full Text] [Related]
18. Cetuximab in colon cancer. Holmer AF N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15470223 [No Abstract] [Full Text] [Related]
19. Market-access agreements for anti-cancer drugs. van de Vooren K; Curto A; Freemantle N; Garattini L J R Soc Med; 2015 May; 108(5):166-70. PubMed ID: 25488094 [No Abstract] [Full Text] [Related]
20. [Drug development in oncology. Its status and outlook with special consideration of the position of Germany]. Strohmeyer T; Weissbach L Dtsch Med Wochenschr; 1999 Feb; 124(8):231-5. PubMed ID: 10093574 [No Abstract] [Full Text] [Related] [Next] [New Search]